GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Metagenomi Inc (NAS:MGX) » Definitions » Capex-to-Operating-Cash-Flow

MGX (Metagenomi) Capex-to-Operating-Cash-Flow : 0.00 (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Metagenomi Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Metagenomi's Capital Expenditure for the three months ended in Dec. 2024 was $-0.33 Mil. Its Cash Flow from Operations for the three months ended in Dec. 2024 was $-26.28 Mil.

GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.


Metagenomi Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Metagenomi's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Metagenomi Capex-to-Operating-Cash-Flow Chart

Metagenomi Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Capex-to-Operating-Cash-Flow
0.12 0.47 - -

Metagenomi Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Metagenomi's Capex-to-Operating-Cash-Flow

For the Biotechnology subindustry, Metagenomi's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Metagenomi's Capex-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Metagenomi's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Metagenomi's Capex-to-Operating-Cash-Flow falls into.


;
;

Metagenomi Capex-to-Operating-Cash-Flow Calculation

Metagenomi's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-3.114) / -109.073
=N/A

Metagenomi's Capex-to-Operating-Cash-Flow for the quarter that ended in Dec. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-0.334) / -26.276
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Metagenomi  (NAS:MGX) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Metagenomi Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Metagenomi's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Metagenomi Business Description

Industry
Traded in Other Exchanges
N/A
Address
5959 Horton Street, 7th Floor, Emeryville, CA, USA, 94608
Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. The genome editing toolbox includes systems for making small edits such as programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), as well as large gene integration systems including large template RIGS and CRISPR-associated transposases (CASTs). The company is focused on its vivo gene editing for its wholly-owned pipeline while pursuing technology out licensing for ex vivo cell therapy. Its pipeline includes product candidates aimed at addressing disorders like Hemophilia A (through MGX-001), Refractory Hypertension, Cardiovascular diseases, and Wilson's disease, among others.

Metagenomi Headlines